Cancer immunotherapy with checkpoint-blocking antibodies targeting Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and PD-1/PD-L1 can cause a long-term sustained response in patients with metastatic cancer of a wide range of histologies. The gene discussed is CD274; the disease is metastatic malignant neoplasm.